Cipla posted an 8% rise in Q2 revenue to ₹75.89 billion and a net profit of ₹13.51 billion, beating estimates. Solid performance across major markets and strategic investments underpin Cipla’s growth and resilience.
Cipla Limited delivered a steady performance for the quarter ended September 30, 2025, reporting consolidated revenue from operations of ₹75.89 billion, surpassing analyst estimates of ₹74.30 billion. The net profit stood at ₹13.51 billion, slightly ahead of expectations, reflecting resilience amid challenging market conditions.
Key Highlights:
-
Cipla’s consolidated revenue from operations grew 8% year-on-year, driven by strong domestic and international sales.
-
The net profit of ₹13.51 billion marks a 4% year-on-year increase, fueled by cost control and product portfolio strength.
-
The company continues to benefit from stable demand across key markets including India, Africa, and Europe.
-
Ongoing investments in research and development support innovation and future growth pipelines.
-
Cipla’s balanced geographic footprint mitigates risks from pricing pressures in certain regulated markets.
-
Analysts note Cipla’s steady execution and strong brand presence in chronic therapies and respiratory segment.
Sources: Reuters, Economic Times, Moneycontrol